1. Gene Therapy Products

Engensis(VM202)

Engensis (VM202) is an innovative gene therapy
drug that provides fundamental treatment through
tissue regeneration.​

개인정보처리방침

닫기

이메일무단수집거부

닫기

Built on 20 years of experience in gene therapy, Engensis is designed to overcome the limitations of previous DNA plasmid candidates by expressing therapeutic levels of protein and inducing durable therapeutic effects.

Helixmith’s non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels.

HGF has a short half-life (5 minutes or less) and is quickly removed from the body by the liver, creating an obstacle to effective treatment with previous injectable recombinant HGF protein products.

A single injection of Helixmith’s proprietary plasmid DNA product expresses the HGF gene at levels 30-40 times higher than conventional plasmid DNA and provides sustained gene expression in mouse models for 2 weeks, with peak protein expression at Day 7 and a gradual decrease over the next week To date, more than 500 patients have been treated with Engensis across ten clinical trials in six different diseases and conditions. Data from previous clinical studies suggest that Engensis is well tolerated and has the potential to provide durable analgesic and/or symptomatic relief in a variety of disease settings. Beyond potentially alleviating pain, Engensis is designed to target the underlying causes of neuropathy through its predicted angiogenic and neuroregenerative properties. The US FDA recognized the potential for Engensis to meet the unmet need for this condition in 2018 by designating it as a Regenerative Medicine Advanced Therapy (RMAT), making it the first RMAT-designated gene therapy for a prevalent disease with over one million patients. This designation grants all the benefits afforded by the fast track and breakthrough designations, including priority review, to Engensis.

Target indications and Mechanisms of action

Status of clinical trials​

Scroll

Indication Pre-clinical Phase 1 Phase 2 Phase 3
Plasmid
DNA
Engensis
(VM202)
Diabetic peripheral neuropathy(DPN)
Diabetic foot ulcers(DFU)
Claudication
Amyotrophic lateral sclerosis
(ALS, Lou Gehrig's Disease)​
Charcot Marie Tooth disease (CMT)
Coronary artery disease (CAD)